Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Nvelop Therapeutics, a new gene editing startup co-founded by David Liu and Keith Joung, has emerged from stealth mode with a $100 million seed round. The company, led by CEO Jeff Walsh and CSO Melissa Bonner, PhD, aims to address the major challenge in gene therapy: the safe and efficient delivery of genetic medicines to patients. Nvelop's approach involves the development of programmable, non-viral delivery platforms based on two in vivo validated approaches, including two viral-like particle (VLP) delivery platforms, leveraging early science from Liu's and Joung's labs. The startup is led by two former bluebird bio executives, indicating a strong leadership team. This launch marks a significant step forward in the gene therapy space, focusing on overcoming delivery challenges to unlock the potential of gene editing therapies.
Noteworthy news out of Nvelop Therapeutics as they launch with $100M to advance research in gene editing using programmable, non-viral delivery platforms built on two in vivo validated approaches. https://t.co/JX1o1X8qwn
The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a startup run by former bluebird bio execs is emerging from stealth to reveal its solutions to the industry. https://t.co/IUUvfJoHqw
9April: How do gene editing pioneers @davidrliu and @JKeithJoung address the challenge of delivering genetic medicines--technologies being developed by newly-launched @nvelop_tx? Hear from CEO Jeff Walsh & CSO Melissa Bonner, PhD in my latest for @GENbio: https://t.co/5IDLrtyeIY
